Retatrutide, developed by Eli Lilly, is a “triple agonist,” a class of medication that interacts with three distinct hormone receptors in the body: glucagon-like peptide-1 (GLP-1), gastric inhibitory polypeptide (GIP), and glucagon. This mechanism distinguishes it from currently approved drugs like semaglutide, which targets only the GLP-1 receptor, and tirzepatide, which targets two. By engaging these three pathways, retatrutide addresses the underlying metabolic dysfunction associated with diabetes while promoting significant weight loss.
The TRIUMPH-2 trial, results for which were published in The Lancet, involved 1,152 participants with obesity and type 2 diabetes. Over an 80-week period, patients received weekly injections of either 4 mg, 9 mg, or 12 mg of retatrutide, or a placebo. The outcomes at the highest dose were substantial. Participants taking 12 mg of retatrutide lost an average of 22.5 kilograms (49.6 pounds), representing more than 20 percent of their starting body weight. This result marks a first for the field, as previous medications had not achieved this level of weight reduction in the diabetic population.
For context, the placebo group lost an average of 4.2 kilograms (9.3 pounds) over the same duration. The difference underscores the potency of the new treatment. Furthermore, the trial demonstrated that between 28.4 and 40 percent of participants, depending on the dose, saw their blood sugar levels normalize by the end of the study. At the 12-mg dose, nearly half of the participants lost 20 percent of their initial weight, while approximately 30 percent lost at least 25 percent.
Clinical and Cardiovascular Implications
Significance of these results extends beyond body mass index (BMI). Gitanjali Srivastava, MD, an obesity medicine specialist and medical director of Vanderbilt Obesity Medicine in Nashville, Tennessee, noted that the population is what makes these results notable. “People with type 2 diabetes have historically lost less weight on obesity medications than people without diabetes,” she said. The ability of retatrutide to overcome this hurdle suggests it can treat both the disease driving the diabetes and the diabetes itself.
Additionally, participants experienced significant reductions in blood sugar, cholesterol, and blood pressure. These metrics are critical risk factors for cardiovascular disease, a leading cause of mortality among patients with type 2 diabetes. By simultaneously addressing obesity and these comorbidities, the drug offers a comprehensive metabolic intervention. Daniel Skovronsky, chief scientific and product officer at Eli Lilly, described the findings as a “new high-water mark for what’s possible in terms of weight loss.”
The drug’s efficacy is not limited to diabetic patients. In a separate trial, TRIUMPH-1, published in the New England Journal of Medicine, participants with obesity but without diabetes achieved up to a 25 percent loss in body weight over 80 weeks. This consistency across populations suggests that the triple-agonist mechanism may provide robust benefits regardless of diabetes status.
Safety and Regulatory Pathway
While the efficacy data is compelling, the safety profile requires careful consideration. Participants in the TRIUMPH-2 trial reported gastrointestinal side effects, including diarrhea, constipation, nausea, and vomiting. The Lancet publication noted that seven deaths occurred during the study; however, these were determined to be unrelated to the treatment.
Retatrutide is currently experimental and has not yet been approved by the U.S. Food and Agency for use by the general public. The phase 3 data represents the gold standard of evidence required for the FDA to consider a drug for approval. As the regulatory process moves forward, clinicians and researchers will continue to monitor long-term safety outcomes. For now, the data provides a clear indication that next-generation weight-loss therapies can deliver unprecedented results for one of the most challenging patient populations in metabolic medicine.
